Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Dec 28;10(12):e044200.
doi: 10.1136/bmjopen-2020-044200.

Reducing cardiovascular disease risk among families with familial hypercholesterolaemia by improving diet and physical activity: a randomised controlled feasibility trial

Affiliations
Randomized Controlled Trial

Reducing cardiovascular disease risk among families with familial hypercholesterolaemia by improving diet and physical activity: a randomised controlled feasibility trial

Fiona Jane Kinnear et al. BMJ Open. .

Abstract

Objective: Familial hypercholesterolaemia (FH) elevates low-density lipoprotein cholesterol (LDL-C) and increases cardiovascular disease (CVD) risk. This study aimed to provide evidence for the feasibility of conducting a randomised controlled trial to evaluate the efficacy of an intervention designed to improve diet and physical activity in families with FH.

Design: A parallel, randomised, waitlist-controlled, feasibility pilot trial.

Setting: Three outpatient lipid clinics in the UK.

Participants: Families that comprised children (aged 10-18 years) and their parent with genetically diagnosed FH.

Intervention: Families were randomised to either 12-week usual care or intervention. The behavioural change intervention aimed to improve dietary, physical activity and sedentary behaviours. It was delivered to families by dietitians initially via a single face-to-face session and then by four telephone or email follow-up sessions.

Outcome measures: Feasibility was assessed via measures related to recruitment, retention and intervention fidelity. Postintervention qualitative interviews were conducted to explore intervention acceptability. Behavioural (dietary intake, physical activity and sedentary time) and clinical (blood pressure, body composition and blood lipids) outcomes were collected at baseline and endpoint assessments to evaluate the intervention's potential benefit.

Results: Twenty-one families (38% of those approached) were recruited which comprised 22 children and 17 adults with FH, and 97% of families completed the study. The intervention was implemented with high fidelity and the qualitative data revealed it was well accepted. Between-group differences at the endpoint assessment were indicative of the intervention's potential for improving diet in children and adults. Evidence for potential benefits on physical activity and sedentary behaviours was less apparent. However, the intervention was associated with improvements in several CVD risk factors including LDL-C, with a within-group mean decrease of 8% (children) and 10% (adults).

Conclusions: The study's recruitment, retention, acceptability and potential efficacy support the development of a definitive trial, subject to identified refinements.

Trial registration number: ISRCTN24880714.

Keywords: cardiology; lipid disorders; nutrition & dietetics; paediatric endocrinology; preventive medicine; qualitative research.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Consolidated Standards of Reporting Trials (CONSORT) diagram of recruitment of families across the three sites. FH, familial hypercholesterolaemia.

References

    1. Goldstein JH, Brown MS. Familial hypercholesterolemia : Sciver CRA, Sly WS, Valle D, The metabolic and molecular bases of inherited disease. 8 edn New York: McGraw-Hill;, 2001: 2863–913.
    1. Beheshti SO, Madsen CM, Varbo A, et al. Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol 2020;75:2553–66. 10.1016/j.jacc.2020.03.057 - DOI - PubMed
    1. Alonso R, Perez de Isla L, Muñiz-Grijalvo O, et al. Barriers to early diagnosis and treatment of familial hypercholesterolemia: current perspectives on improving patient care. Vasc Health Risk Manag 2020;16:11–25. 10.2147/VHRM.S192401 - DOI - PMC - PubMed
    1. Bianconi V, Banach M, Pirro M, et al. Why patients with familial hypercholesterolemia are at high cardiovascular risk? beyond LDL-C levels. Trends Cardiovasc Med 2020. 10.1016/j.tcm.2020.03.004. [Epub ahead of print: 12 Mar 2020]. - DOI - PubMed
    1. Galema-Boers AM, Lenzen MJ, Engelkes SR, et al. Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy. J Clin Lipidol 2018;12:409–16. 10.1016/j.jacl.2017.12.014 - DOI - PubMed

Publication types

Associated data

LinkOut - more resources